
Annexon, Inc (ANNX) Stock Forecast & Price Target
Annexon, Inc (ANNX) Analyst Ratings
Bulls say
Annexon is a promising biotech company with a promising pipeline of C1q inhibitors targeting various autoimmune disorders, including GA and GBS. However, challenges remain in gaining market share and ensuring financial stability, with concerns about potential vision loss and uncertainties around regulatory approval. Management is working to increase the chances of success in their Phase 3 trials, and the potential market for their lead program in the U.S. and globally is significant.
Bears say
Annexon is facing competition from other companies developing drugs targeting the complement pathway which may limit their market share. Furthermore, their current drugs in development have shown limitations in Phase 2 trials and additional capital may be needed in the future. The company is led by an experienced CEO but may need to differentiate their drugs to stand out in the market and be profitable in the next few years.
This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.
Annexon, Inc (ANNX) Analyst Forecast & Price Prediction
Start investing in Annexon, Inc (ANNX)
Order type
Buy in
Order amount
Est. shares
0 shares